Lung surfactant in subacute pulmonary disease

Respiratory Research

Roger G Spragg¹  Gehan Devendra² 

[1] San Diego Veterans Affairs Medical Center, San Diego, California, USA;University of California, San Diego, California, USA

关键词: pulmonary surfactant;    pulmonary alveolar proteinosis;    pneumonia;    interstitial pulmonary fibrosis;    asthma;   

Others  :  1227401
DOI  :  10.1186/rr168

 received in 2001-11-01, accepted in 2002-02-20,  发布年份 2002

【 摘 要 】

Pulmonary surfactant is a surface active material composed of both lipids and proteins that is produced by alveolar type II pneumocytes. Abnormalities of surfactant in the immature lung or in the acutely inflamed mature lung are well described. However, in a variety of subacute diseases of the mature lung, abnormalities of lung surfactant may also be of importance. These diseases include chronic obstructive pulmonary disease, asthma, cystic fibrosis, interstitial lung disease, pneumonia, and alveolar proteinosis. Understanding of the mechanisms that disturb the lung surfactant system may lead to novel rational therapies for these diseases.

【 授权许可】

   
2002 BioMed Central Ltd

【 参考文献 】

• [1]Crouch E, Wright JR: Surfactant proteins A and D and pulmonary host defense. Annu Rev Physiol 2001, 63:521-554.
• [2]Enhorning G, Duffy LC, Welliver RC: Pulmonary surfactant maintains patency of conducting airways in the rat. Am J Respir Crit Care Med 1995, 151:554-556.
• [3]Veletza SV, Rogan PK, TenHave T, Olowe SA, Floros J: Racial differences in allelic distribution at the human pulmonary surfactant protein B gene locus (SP-B). Exp Lung Res 1996, 22:489-494.
• [4]Nogee LM, Dunbar AE, Wert SE, Askin F, Hamvas A, Whitsett JA: A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001, 344:573-579.
• [5]Wang Z, Notter RH: Additivity of protein and nonprotein inhibitors of lung surfactant activity. Am J Respir Crit Care Med 1998, 158:28-35.
• [6]Zhu S, Basiouny KF, Crow JP, Matalon S: Carbon dioxide enhances nitration of surfactant protein A by activated alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2000, 278:L1025-L1031.
• [7]Hohlfeld J, Fabel H, Hamm H: The role of pulmonary surfactant in obstructive airways disease. Eur Respir J 1997, 10:482-491.
• [8]Kurashima K, Fujimura M, Matsuda T, Kobayashi T: Surface activity of sputum from acute asthmatic patients. Am J Respir Crit Care Med 1997, 155:1254-1259.
• [9]Liu M, Wang L, Enhorning G: Surfactant dysfunction develops when the immunized guinea-pig is challenged with ovalbumin aerosol. Clin Exp Allergy 1995, 25:1053-1060.
• [10]Becher G: Lung surfactant prevents allergic bronchial constriction in ovalbumin sensitized guinea pigs. Biomed Biochim Acta 1985, 44:K57-K61.
• [11]Cheng G, Ueda T, Sugiyama K, Toda M, Fukuda T: Compositional and functional changes of pulmonary surfactant in a guinea-pig model of chronic asthma. Respir Med 2001, 95:180-186.
• [12]Oetomo SB, Dorrepaal C, Bos H, Gerritsen J, van der Mark TW, Koeter GH, van Aalderen WM: Surfactant nebulization does not alter airflow obstruction and bronchial responsiveness to histamine in asthmatic children. Am J Respir Crit Care Med 1996, 153:1148-1152.
• [13]Kurashima K, Ogawa H, Ohka T, Fujimura M, Matsuda T, Kobayashi T: A pilot study of surfactant inhalation in the treatment of asthmatic attack. Arerugi 1991, 40:160-163.
• [14]Wirtz HR, Schmidt M: Acute influence of cigarette smoke on secretion of pulmonary surfactant in rat alveolar type II cells in culture. Eur Respir J 1996, 9:24-32.
• [15]Repine JE, Bast A, Lankhorst I: Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997, 156:341-357.
• [16]Honda Y, Takahashi H, Kuroki Y, Akino T, Abe S: Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Chest 1996, 109:1006-1009.
• [17]Anzueto A, Jubran A, Ohar JA, Piquette CA, Rennard SI, Colice G, Pattishall EN, Barrett J, Engle M, Perret KA, Rubin BK: Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA 1997, 278:1426-1431.
• [18]Griese M, Birrer P, Demirsoy A: Pulmonary surfactant in cystic fibrosis. Eur Respir J 1997, 10:1983-1988.
• [19]von Bredow C, Birrer P, Griese M: Surfactant protein A and other bronchoalveolar lavage fluid proteins are altered in cystic fibrosis. Eur Respir J 2001, 17:716-722.
• [20]Griese M, Bufler P, Teller J, Reinhardt D: Nebulization of a bovine surfactant in cystic fibrosis: a pilot study. Eur Respir J 1997, 10:1989-1994.
• [21]Schmidt R, Meier U, Yabut-Perez M, Walmrath D, Grimminger F, Seeger W, Günther A: Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia. Am J Respir Crit Care Med 2001, 163:95-100.
• [22]Mikawa K, Maekawa N, Nishina K, Takao Y, Yaku H, Obara H: Selective intrabronchial instillation of surfactant in a patient with pneumonia: a preliminary report. Eur Respir J 1993, 6:1563-1566.
• [23]Günther A, Schmidt R, Nix F, Yabut-Perez M, Guth C, Rosseau S, Siebert C, Grimminger F, Morr H, Velcovsky HG, Seeger W: Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis. Eur Respir J 1999, 14:565-573.
• [24]Takahashi H, Kuroki Y, Tanaka H, Saito T, Kurokawa K, Chiba H, Sagawa A, Nagae H, Abe S: Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000, 162:258-263.
• [25]McCormack FX, King TEJ, Bucher BL, Nielsen L, Mason RJ, McCormac FX: Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995, 152:751-759.
• [26]Hamm H, Luhrs J, Guzman , Costabel U, Fabel H, Bartsch W: Elevated surfactant protein A in bronchoalveolar lavage fluids from sarcoidosis and hypersensitivity pneumonitis patients. Chest 1994, 106:1766-1770.
• [27]Reed JA, Ikegami M, Cianciolo ER, Lu W, Cho PS, Hull W, Jobe AH, Whitsett JA: Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Am J Physiol 1999, 276:L556-L563.
• [28]Kitamura T, Tanaka N, Watanabe J, Uchida K, Kanegasaki S, Yamada Y, Nakata K: Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999, 190:875-880.
• [29]Doyle IR, Davidson KG, Barr HA, Nicholas TE, Payne K, Pfitzner J: Quantity and structure of surfactant proteins vary among patients with alveolar proteinosis. Am J Respir Crit Care Med 1998, 157:658-664.
• [30]Suzuki Y, Shen HQ, Sato A, Nagai S: Analysis of fused-membrane structures in bronchoalveolar lavage fluid from patients with alveolar proteinosis. Am J Respir Cell Mol Biol 1995, 12:238-249.
• [31]Kavuru MS, Sullivan EJ, Piccin R, Thomassen MJ, Stoller JK: Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000, 161:1143-1148.